Sperti C, Militello C, Rovati L, Behboo R, Khajeturian E, Perasole A, Alaggio R, Pedrazzoli S
Department of Surgery, University of Padua, Italy.
J Surg Oncol. 1994 Sep;57(1):11-6. doi: 10.1002/jso.2930570105.
The effects of the cholecystokinin (CCK)-analogue, caerulein, and CCK-receptor antagonist lorglumide (CR-1409) on pancreatic carcinogenesis induced by 7,12-dimethylbenz(a)anthracene (DMBA) were studied. One hundred thirty rats were divided into the following 10 treatment groups: group 1, DMBA (2-3 mg); group 2, DMBA + caerulein (5 micrograms/kg); group 3, DMBA + caerulein + CR-1409 (12 mg/kg); group 4, caerulein + DMBA; group 5, caerulein + CR-1409 + DMBA; group 6, DMBA + CR-1409; group 7, CR-1409 + DMBA; group 8, caerulein; group 9, CR-1409; and group 10, sham operation + saline. DMBA was surgically implanted into the pancreas. Caerulein and/or CR-1409 was administered twice daily for 15 days after (in groups 2, 3, and 6) or before (in groups 4, 5, and 7) DMBA implantation. Six months after carcinogen administration, all rats were sacrificed and autopsied. The incidence of pancreatic cancer appeared significantly (P < 0.001) increased when caerulein was administered following DMBA implantation. CR-1409 significantly inhibited (P < 0.02) caerulein effects and reduced tumor growth when injected after carcinogen exposure.
研究了胆囊收缩素（CCK）类似物蛙皮素和CCK受体拮抗剂洛谷胺（CR - 1409）对7,12 - 二甲基苯并（a）蒽（DMBA）诱导的胰腺癌发生的影响。130只大鼠被分为以下10个治疗组：第1组，DMBA（2 - 3毫克）；第2组，DMBA + 蛙皮素（5微克/千克）；第3组，DMBA + 蛙皮素 + CR - 1409（12毫克/千克）；第4组，蛙皮素 + DMBA；第5组，蛙皮素 + CR - 1409 + DMBA；第6组，DMBA + CR - 1409；第7组，CR - 1409 + DMBA；第8组，蛙皮素；第9组，CR - 1409；第10组，假手术 + 生理盐水。将DMBA手术植入胰腺。在DMBA植入后（第2、3和6组）或之前（第4、5和7组），蛙皮素和/或CR - 1409每日给药两次，共15天。给予致癌物6个月后，所有大鼠均被处死并进行尸检。当在DMBA植入后给予蛙皮素时，胰腺癌的发生率显著升高（P < 0.001）。在致癌物暴露后注射CR - 1409可显著抑制（P < 0.02）蛙皮素的作用并减少肿瘤生长。
